Connect with us

National

Coronavirus Live News Update: WHO Official Says “India May Be Entering Endemic Stage Of Covid” – dot newz

Published

on


Coronavirus Live Updates: India added 25,467 new COVID-19 cases Tuesday.

COVID-19 in India may be entering some kind of stage of endemicity where there is low or moderate level of transmission going on, Chief Scientist of the World Health Organisation Dr Soumya Swaminathan said. The endemic stage is when a population learns to live with a virus. It’s very different from the epidemic stage when the virus overwhelms a population.

On clearance to Covaxin, she said she is fairly confident that the WHO’s technical group will be satisfied to give Covaxin clearance to be one of its authorised vaccines and that could happen by mid-September.

India added 25,467 new COVID-19 cases, while the active cases declined to 3,19,551, comprising 0.98 per cent of the total infections, the lowest since March 2020, according to the Union Health Ministry data updated on Tuesday.

Here are LIVE Updates on Coronavirus Cases:

Delta Variant Cases Show 300 Times Higher Viral Load, Shows South Korea Study
People infected with the more transmissible Delta variant have a viral load 300 times higher than those with the original version of the COVID-19 virus when symptoms are first observed, a South Korea study found.

But the amount gradually decreased over time – to 30 times in four days and over 10 times in nine days – and it matched levels seen in other variants after 10 days, the Korea Disease Control and Prevention Agency (KDCA) said on Tuesday.

The higher load means the virus spreads far more easily from person to person, increasing infections and hospitalisations, a health ministry official Lee Sang-won told a news conference.

‘India May Be Entering Endemic Stage Of Covid’: WHO Chief Scientist
COVID-19 in India may be entering some kind of stage of endemicity where there is low or moderate level of transmission going on, Chief Scientist of the World Health Organisation Dr Soumya Swaminathan said.
The endemic stage is when a population learns to live with a virus. It’s very different from the epidemic stage when the virus overwhelms a population.

On clearance to Covaxin, she said she is fairly confident that the WHO’s technical group will be satisfied to give Covaxin clearance to be one of its authorised vaccines and that could happen by mid-September.

In an interview to journalist Karan Thapar for news website The Wire, Ms Swaminathan said given the size of India and heterogeneity of population and immunity status in different parts of the country, it is “very very feasible” that the situation may continue like this with ups and downs in various parts of the nation.

“We may be entering some kind of stage of endemicity where there is low level transmission or moderate level transmission going on but we are not seeing the kinds of exponential growth and peaks that we saw a few months ago,” Ms Swaminathan said.

“As far as India is concerned that seems to be what is happening and because of size of India and heterogeneity of population and immunity status in different parts of country in different pockets, it is very very feasible that the situation may continue like this with ups and downs in different parts of the country, particularly where there are more susceptible population, so those groups who were perhaps less affected by first and second waves or those areas with low levels of vaccine coverage we could see peaks and troughs for the next several months,” she said.



Source link

National

Coronavirus Live News Update: India Creates World Record In Vaccinations With 2.5 Crore Doses In A Day – dot newz

Published

on

By


The government had set out with a target of 2.5 crore vaccinations and crossed the mark by 10,390

India crossed 2.5 crore Covid vaccinations in a day for the first time on Friday as the government raced to deliver a record on Prime Minister Narendra Modi’s birthday. Union Health Minister Mansukh Mandaviya tweeted to confirm the “historic” figure.

The government had set out with a target of 2.5 crore vaccinations and crossed the mark by 10,390.

With 34,403 more people testing positive for COVID-19, India’s overall infection tally has increased to 3,33,81,728, while the count of active cases has dipped to 3,39,056, according to Union health ministry data updated on Friday.

The death count due to the disease has climbed to 4,44,248 with 320 more fatalities being recorded, it said.

The number of active cases now comprises 1.03 per cent of the total infections, while the national COVID-19 recovery rate has been recorded at 97.64 per cent, according to the data updated by the ministry.

It said that active COVID-19 cases in the country decreased by 3,867 cases in a span of 24 hours.

Here are the updates on coronavirus (COVID-19) cases:

Over 7 lakh people vaccinated in Assam on PM’s birthday

A total of 7,09,524 people received the COVID-19 vaccine in Assam on Friday as the state government undertook a mega inoculation drive on the occasion of Prime Minister Narendra Modi’s birthday, a bulletin said.

Over 2.16 crore people have been immunised, and 44.02 lakh of them got both doses of the vaccines, it said.

The special drive was conducted in 4,575 COVID Vaccination Centres (CVCs), of which 4,557 were government sites and 18 private ones.



Source link

Continue Reading

National

WHO Emergency Approval For Covaxin Delayed Till October 5 – dot newz

Published

on

By


The assessment of the SAGE working group on the available pieces of evidence will determine EUA.

New Delhi:

World Health Organisation’s (WHO) approval for the emergency use authorisation (EUA) to COVID-19 vaccine Covaxin, developed by the Hyderabad-based Bharat Biotech, is likely to be delayed till October 5.

As per WHO, the Strategic Advisory Group of Experts on Immunization (SAGE) will be meeting on October 5 to granting EUA to Covaxin.

Hanna Nohynek, SAGE member will be introducing session objective setting, an update on regulatory decisions and an overview of Working Group deliverables.

The session will recommend EUA based on the clinical data on Covaxin from phase 1, 2, 3 trial and post-marketing studies on safety, immunogenicity, efficacy and effectiveness.

It will update on global, regional and country-level plans for vaccine safety monitoring.

The assessment of the SAGE working group on the available pieces of evidence will determine EUA.

Meanwhile, Bharat Biotech on Friday said it has submitted all the data to the World Health Organisation (WHO) for Emergency Use Listing (EUL) of its COVID-19 vaccine Covaxin and is awaiting feedback from the UN Public Health Agency.

In a series of tweets, Bharat Biotech said that Covaxin clinical trial was fully compiled and available in June 2021.

“#COVAXIN clinical trial data was fully compiled and available in June 2021. All Data was submitted for Emergency Use Listing (EUL) Application to World Health Organization in early July. We have responded to any clarifications sought by #WHO and are awaiting further feedback,” Bharat Biotech tweeted.

As a responsible manufacturer with past approvals for its other vaccines, the company said it would not find it appropriate to speculate or comment on the approval process and its timelines, it further said.

“We are continuing to work diligently on obtaining WHO EUL at the earliest,” it added.

Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

Covaxin was developed by Hyderabad-based Bharat Biotech in association with the Indian Council of Medical Research and the National Institute of Virology. Covaxin, which has been developed in collaboration with the Indian Council of Medical Research (ICMR), contains a whole virion inactivated SARS-CoV-2 vaccine, which is produced in Vero cells.

The vaccine is stable at 2 degrees Celsius to 8 degrees Celsius (refrigerated) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels.

The WHO has so far approved Covid vaccines developed by Pfizer-BioNTech, US pharma majors Johnson & Johnson, Moderna, China’s Sinopharm and Oxford-AstraZeneca for emergency use.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)





Source link

Continue Reading

National

PM Praises Frontline, Health Workers As India Administers Over 2 Crore Doses – dot newz

Published

on

By


PM Praises Frontline, Health Workers As India Administers Record Doses

New Delhi:

As India set a new record on Friday by administering over 2 crores COVID-19 vaccine doses, Prime Minister Narendra Modi dedicated the success of the vaccination drive to the country’s doctors, innovators, administrators, nurses, healthcare and all front-line workers.

“Every Indian would be proud of today’s record vaccination numbers. I acknowledge our doctors, innovators, administrators, nurses, healthcare and all front-line workers who have toiled to make the vaccination drive a success. Let us keep boosting vaccination to defeat COVID-19,” PM Modi tweeted.

Bharatiya Janata Party (BJP) and several state governments have aimed to make Prime Minister Narendra Modi’s birthday historic by setting a record number of Covid vaccinations Friday.

Taking to Twitter, Union Health Minister Mansukh Mandaviya said that the historic feat is a gift to PM Modi on behalf of the health workers and the countrymen.

“#VaccineSeva A gift to Prime minister Narendra Modi on behalf of the health workers and the countrymen. Today, on his birthday, India has crossed the historical figure of administering 2 crore vaccines in a day, setting a new record. Well done India!” Mandaviya tweeted.

India has administered more than one crore COVID-19 vaccines in a day on earlier occasions.The vaccination drive in the country commenced on January 16 with the inoculation of healthcare and frontline workers. At present, India is administering COVID-19 vaccines– Covishield of Serum Institute of India (SII), Bharat Biotech”s Covaxin and Sputnik V.

To ramp up the drive, on April 1, the government had opened Covid-19 vaccination for everyone above the age of 45 years. A month later from May 1, as a part of the third phase of the vaccination drive, India began administering the vaccine in the 18 to 44 years age group.

Since then, the country’s vaccination drive is scaling new heights. On August 9, India’s COVID-19 vaccination coverage crossed the landmark of 50 crores.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)





Source link

Continue Reading

Trending

Copyright © 2017 Dot Newz | Developed by MCVP Group 8